Logo image of ARWR

ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Fundamental Analysis

NASDAQ:ARWR - US04280A1007 - Common Stock

27.73 USD
-0.02 (-0.07%)
Last: 9/9/2025, 4:30:01 PM
27.73 USD
0 (0%)
After Hours: 9/9/2025, 4:30:01 PM
Fundamental Rating

3

Overall ARWR gets a fundamental rating of 3 out of 10. We evaluated ARWR against 541 industry peers in the Biotechnology industry. While ARWR seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ARWR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARWR had negative earnings in the past year.
In the past year ARWR had a positive cash flow from operations.
ARWR had negative earnings in each of the past 5 years.
In the past 5 years ARWR reported 4 times negative operating cash flow.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

ARWR has a better Return On Assets (-10.75%) than 82.81% of its industry peers.
ARWR has a Return On Equity of -28.42%. This is in the better half of the industry: ARWR outperforms 78.56% of its industry peers.
Industry RankSector Rank
ROA -10.75%
ROE -28.42%
ROIC N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

ARWR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

4

2. Health

2.1 Basic Checks

ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARWR has more shares outstanding
ARWR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARWR has a worse debt to assets ratio.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ARWR has an Altman-Z score of 1.87. This is not the best score and indicates that ARWR is in the grey zone with still only limited risk for bankruptcy at the moment.
ARWR has a better Altman-Z score (1.87) than 66.54% of its industry peers.
A Debt/Equity ratio of 0.38 indicates that ARWR is not too dependend on debt financing.
ARWR's Debt to Equity ratio of 0.38 is on the low side compared to the rest of the industry. ARWR is outperformed by 71.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 1.87
ROIC/WACCN/A
WACC9.54%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

2.3 Liquidity

ARWR has a Current Ratio of 4.87. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.87, ARWR perfoms like the industry average, outperforming 52.87% of the companies in the same industry.
ARWR has a Quick Ratio of 4.87. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
ARWR has a Quick ratio (4.87) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 4.87
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

ARWR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.75%, which is quite impressive.
Looking at the last year, ARWR shows a very strong growth in Revenue. The Revenue has grown by 2816.21%.
The Revenue for ARWR have been decreasing by -53.80% on average. This is quite bad
EPS 1Y (TTM)72.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
Revenue 1Y (TTM)2816.21%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%N/A

3.2 Future

ARWR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.82% yearly.
ARWR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 60.01% yearly.
EPS Next Y104.76%
EPS Next 2Y16.32%
EPS Next 3Y9.48%
EPS Next 5Y14.82%
Revenue Next Year941%
Revenue Next 2Y118.53%
Revenue Next 3Y66.11%
Revenue Next 5Y60.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARWR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.32%
EPS Next 3Y9.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARWR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (9/9/2025, 4:30:01 PM)

After market: 27.73 0 (0%)

27.73

-0.02 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-24 2025-11-24/amc
Inst Owners78.88%
Inst Owner Change0.8%
Ins Owners3.82%
Ins Owner Change1.6%
Market Cap3.83B
Analysts78.1
Price Target44.88 (61.85%)
Short Float %9.83%
Short Ratio6.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)720.57%
Min EPS beat(2)-20.51%
Max EPS beat(2)1461.66%
EPS beat(4)1
Avg EPS beat(4)300.4%
Min EPS beat(4)-211.36%
Max EPS beat(4)1461.66%
EPS beat(8)1
Avg EPS beat(8)53.33%
EPS beat(12)2
Avg EPS beat(12)-1.35%
EPS beat(16)3
Avg EPS beat(16)3.1%
Revenue beat(2)2
Avg Revenue beat(2)847.45%
Min Revenue beat(2)14.81%
Max Revenue beat(2)1680.09%
Revenue beat(4)2
Avg Revenue beat(4)374.57%
Min Revenue beat(4)-100%
Max Revenue beat(4)1680.09%
Revenue beat(8)2
Avg Revenue beat(8)142.65%
Revenue beat(12)3
Avg Revenue beat(12)98.93%
Revenue beat(16)4
Avg Revenue beat(16)68.75%
PT rev (1m)0%
PT rev (3m)-1.12%
EPS NQ rev (1m)104.71%
EPS NQ rev (3m)102.55%
EPS NY rev (1m)464.4%
EPS NY rev (3m)108.43%
Revenue NQ rev (1m)1.83%
Revenue NQ rev (3m)252.96%
Revenue NY rev (1m)-0.35%
Revenue NY rev (3m)1.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.69
P/FCF N/A
P/OCF 175.51
P/B 7.34
P/tB 7.44
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-3.24
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.16
OCFY0.57%
SpS4.14
BVpS3.78
TBVpS3.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.75%
ROE -28.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 174.88%
Cap/Sales 6.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.87
Quick Ratio 4.87
Altman-Z 1.87
F-Score6
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)894.03%
Cap/Depr(5y)633.96%
Cap/Sales(3y)1359.68%
Cap/Sales(5y)821.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
EPS Next Y104.76%
EPS Next 2Y16.32%
EPS Next 3Y9.48%
EPS Next 5Y14.82%
Revenue 1Y (TTM)2816.21%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%N/A
Revenue Next Year941%
Revenue Next 2Y118.53%
Revenue Next 3Y66.11%
Revenue Next 5Y60.01%
EBIT growth 1Y80.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year121.54%
EBIT Next 3Y-0.59%
EBIT Next 5Y10.82%
FCF growth 1Y94.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y111.08%
OCF growth 3YN/A
OCF growth 5YN/A